ARTICLE | Clinical News
SGN-15 (BR96): Began Phase II trial
August 27, 2001 7:00 AM UTC
Seattle Genetics Inc., Bothell, Wash. Product: SGN-15 (BR96) Business: Cancer Therapeutic category: Antibody, Cytotoxic Target: Lewis Y antigen Description: Monoclonal antibody (MAb) chemically linke...